Chen, Joseph
Bearz, Alessandra
Kim, Dong-Wan
Mamdani, Hirva
Bauman, Jessica
Chiari, Rita
Ou, Sai-Hong Ignatius
Solomon, Benjamin J.
Soo, Ross A.
Felip, Enriqueta
Shaw, Alice T.
Thurm, Holger
Clancy, Jill S.
Lee, Kimberly
O’Gorman, Melissa
Tanski, Cherie
Pithavala, Yazdi K.
Funding for this research was provided by:
Pfizer
Article History
Accepted: 12 September 2023
First Online: 11 December 2023
Declarations
:
: JC, HT, JSC, KL, MO, CT, and YKP analyzed the data. AB, D-WK, HM, JB, RC, S-HIO, BJS, RAS, EF, and AS collected the data. All authors contributed to the interpretation of the data and the development, writing, and approval of the manuscript.
: This study was sponsored by Pfizer.
: JC was employed by Pfizer at the time of the work, owns stocks in Pfizer, and is currently employed by Roche/Genentech. AB reports advisory board fees from AstraZeneca, Bristol Myers Squibb, Pfizer, and Roche; speaker fees from Eli Lilly, Pfizer, and Roche. D-WK reports administrative support and grants from Amgen, AstraZeneca, Boehringer Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi Sankyo, GlaxoSmithKline, Janssen, Merck, Merus, MSD, Novartis, Pfizer, Roche, Takeda, and Yuhan; grants from Alpha Biopharma, Hanmi, InnoN, Mirati Therapeutics, ONO Pharmaceutical, Turning Point Therapeutics, and Xcovery. HM reports advisory board fees from AstraZeneca, Genentech, and Zentalis; received a grant from U CAN-CER VIVE Foundation; and received institutional research funding from Pfizer. JB reports consulting fees or honoraria from BeiGene, Blueprint Medicines, Eli Lilly, Janssen, Merck, Mirati, Pfizer, and Turning Point Therapeutics. RC declares no conflicts of interest. S-HIO reports consulting fees or honorarium from AnHeart Therapeutics, BeiGene, Daiichi Sankyo, Eli Lilly, Johnson and Johnson/Janssen, and Pfizer; speaker fees from DAVA Oncology, Johnson and Johnson/Janssen, and Pfizer; advisory board fees from Elevation Oncology; stocks in Elevation Oncology and Turning Point Therapeutics. BJS reports advisory board fees or honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Pfizer, Roche/Genentech; and received fees from BeiGene, Janssen, Novartis, and Takeda. RAS reports advisory board fees or honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, J INTS BIO, Janssen, Merck, Microquin, Novartis, Pfizer, Puma Biotechnology, Roche, Taiho, Takeda, ThermoFisher, and Yuhan; and research grants from AstraZeneca and Boehringer Ingelheim. EF reports consulting fees or honoraria from Amgen, AstraZeneca, BerGenBio, Bristol Myers Squibb, Daichi Sankyo, Eli Lilly, F. Hoffman-La Roche, GlaxoSmithKline, Janssen, Merck Serono, MSD, Novartis, Peptomyc, Pfizer, Sanofi, and Takeda; speaker fees from Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Janssen, Medical Trends, MedScape, MSD, Novartis, PeerVoice, Pfizer, Sanofi, Takeda, and Touch Oncology; and is an independent member of the board at Grifols. AS is employed by and owns stock in Novartis. HT, JSC, KL, MO, CT, and YKP are employed by and own stocks in Pfizer.
: Upon request and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See ExternalRef removed for more information.
: The independent ethics committee or institutional review board at each site approved the protocol. The protocol complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws.
: Before participation, all patients provided written informed consent.
: All authors had the final responsibility for the decision to submit the publication.
: Not applicable.